当前位置:首页 > 医源资料库 > 医学文档库 > 心血管相关 > LIFE研究

LIFE研究

The LIFE Trial
Losartan Intervention For Endpoint reduction in hypertension study (LIFE)

Presented at the American College of Cardiology
51st Annual Scientific Session
Atlanta, GA

Dr Bj?rn Dahl?f
for the LIFE Investigators
LIFE: Major clinical end points in patients with ISH
RR=risk ratio
Kjeldsen SE et al. JAMA 2002;288:1491-98.
LIFE: Major clinical end points in patients without ISH
RR=risk ratio
Kjeldsen SE et al. JAMA 2002;288:1491-98.
Patients with hypertension (blood pressure 160-200/ 95-115 mm Hg)
and left ventricular hypertrophy
Atenolol
Beta-blocker
Dose titrated to BP <140/90 mm Hg

(n=4,588)
Losartan
Angiotensin II antagonist
Dose titrated to BP <140/90 mm Hg

(n=4,605)
Followed for >4 years - Mean follow-up 4.8 years
Cardiovascular death, MI, stroke
LIFE: Study Design
Losartan
Atenolol
P=0.021
Composite of CV Death / MI / Stroke
LIFE: Primary Composite Endpoint
Adjusted Hazard Ratio = 0.87
Rate 23.8/1,000
patient yrs
Rate 27.9/1,000
patient yrs
n=508
n=588
P=0.206
P=0.491
Cardiovascular Death
Myocardial Infarction
P=0.001
Stroke
LIFE: Individual Endpoint Results
Adjusted HR 0.89
Adjusted HR 1.07
Adjusted HR 0.75
Losartan
Atenolol
Losartan
Atenolol
Losartan
Atenolol
Losartan
Atenolol
P=0.001
LIFE: New-onset diabetes
Adjusted Hazard Ratio = 0.75
Rate 13.0/1,000
patient yrs
Rate 17.4/1,000
patient yrs
n=241
n=319


医学百科App—医学基础知识学习工具


页:
返回顶部】【打印本文】【放入收藏夹】【收藏到新浪】【发布评论



察看关于《LIFE研究》的讨论


关闭

网站地图 | RSS订阅 | 图文 | 版权说明 | 友情链接
Copyright © 2008 39kf.com All rights reserved. 医源世界 版权所有
医源世界所刊载之内容一般仅用于教育目的。您从医源世界获取的信息不得直接用于诊断、治疗疾病或应对您的健康问题。如果您怀疑自己有健康问题,请直接咨询您的保健医生。医源世界、作者、编辑都将不负任何责任和义务。
本站内容来源于网络,转载仅为传播信息促进医药行业发展,如果我们的行为侵犯了您的权益,请及时与我们联系我们将在收到通知后妥善处理该部分内容
联系Email: